Valuation: ACLS THER

Market Cap 715M 628M 587M 538M 1.01B 68.49B 1.03B 6.95B 2.72B 33.89B 2.68B 2.63B 117B P/E 2026 *
-7.89x
P/E 2027 * -6.43x
Enterprise Value 579M 509M 475M 436M 817M 55.5B 837M 5.64B 2.2B 27.47B 2.18B 2.13B 94.95B EV / Sales 2026 *
101x
EV / Sales 2027 * 110x
Free-Float
97.72%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 16/01/2024
President 67 17/11/2024
Director of Finance/CFO 39 31/12/2022
Director TitleAgeSince
Chairman 56 31/12/2022
Director/Board Member 50 31/08/2014
Director/Board Member 59 31/08/2016
Change 5-day change 1-year change 3-year change Capi.($)
-2.99%-5.55%+43.88%+64.73% 55.2B
+2.83%+0.48%+28.18%+82.59% 55.6B
-0.17%+0.70%-15.77%-14.85% 23.51B
-1.92%-5.34%-3.33%+360.28% 22.35B
-4.01%-3.67%+13.17%-14.29% 20.6B
-1.98%-3.86%+25.08%-34.32% 17.45B
-3.34%-7.77%+23.78%+536.66% 15.16B
-0.68%-1.06%+49.40%+179.35% 13.91B
-3.14%-8.47%+165.37%+292.18% 13.74B
Average -1.70%-1.27%+36.64%+161.37% 26.39B
Weighted average by Cap. -1.15%-0.52%+31.88%+124.71%

Financials

2026 *2027 *
Net sales 5.71M 5.02M 4.69M 4.3M 8.05M 547M 8.25M 55.56M 21.73M 271M 21.45M 20.98M 936M 5.36M 4.71M 4.39M 4.03M 7.55M 513M 7.74M 52.12M 20.38M 254M 20.12M 19.68M 878M
Net income -84.78M -74.5M -69.54M -63.82M -119M -8.12B -122M -825M -322M -4.02B -318M -311M -13.89B -103M -90.08M -84.08M -77.17M -144M -9.82B -148M -997M -390M -4.86B -385M -377M -16.8B
Net Debt -136M -119M -111M -102M -191M -12.99B -196M -1.32B -516M -6.43B -509M -498M -22.22B -125M -110M -102M -94.02M -176M -11.96B -180M -1.21B -475M -5.92B -469M -459M -20.47B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-